Primary Retroperitoneal Mucinous Cystadenocarcinoma during Long-term Administration of Infliximab for the Treatment of Crohn's Disease

Intern Med. 2023 Dec 15;62(24):3619-3624. doi: 10.2169/internalmedicine.1593-23. Epub 2023 May 10.

Abstract

We herein report a rare case of primary retroperitoneal mucinous cystadenocarcinoma (PRMC) in a 60-year-old man. The patient, who had been treated with infliximab for Crohn's disease of the colon for 13 years, was referred to our hospital for lower back pain. Contrast-enhanced computed tomography (CT) and magnetic resonance imaging revealed multiple cystic lesions in the right retroperitoneum, the calcification of the cyst, and bone lesions. Bone and CT-assisted biopsies of the retroperitoneal lesions revealed poorly differentiated adenocarcinoma. The patient was diagnosed with PRMC with bone metastases using immunohistochemical staining and positron emission tomography/CT.

Keywords: Crohn's disease; infliximab; multiple cystic lesions; primary retroperitoneal mucinous cystadenocarcinoma.

Publication types

  • Case Reports

MeSH terms

  • Crohn Disease* / complications
  • Crohn Disease* / drug therapy
  • Cystadenocarcinoma, Mucinous* / diagnostic imaging
  • Cystadenocarcinoma, Mucinous* / drug therapy
  • Cystadenocarcinoma, Mucinous* / pathology
  • Humans
  • Infliximab / adverse effects
  • Male
  • Middle Aged
  • Retroperitoneal Neoplasms* / diagnostic imaging
  • Retroperitoneal Neoplasms* / drug therapy
  • Tomography, X-Ray Computed

Substances

  • Infliximab